ar-c239 has been researched along with Cardiac Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Besse, P; Colle, JP | 1 |
| Besse, P; Colle, JP; Hilaire, J; Ohayon, J | 1 |
2 other study(ies) available for ar-c239 and Cardiac Failure
| Article | Year |
|---|---|
Hemodynamic effects of continuous infusion of AR-C 239 in left ventricular failure.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Cardiac Output; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Piperazines | 1989 |
[Hemodynamic effects of a new alpha-1 antagonist, AR-C 239 administrated in intravenous bolus, in patients with cardiac insufficiency].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Piperazines; Time Factors; Vasodilator Agents | 1987 |